Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 6473204, 16 pages
http://dx.doi.org/10.1155/2016/6473204
Research Article

Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients

1Department of Autoimmunology and Biomarkers, Statens Serum Institut, 2300 Copenhagen, Denmark
2Department of Congenital Disorders, Statens Serum Institut, 2300 Copenhagen, Denmark
3Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark

Received 12 November 2015; Accepted 6 March 2016

Academic Editor: Ethan M. Shevach

Copyright © 2016 Anette Holck Draborg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. J. Pons-Estel, G. S. Alarcón, L. Scofield, L. Reinlib, and G. S. Cooper, “Understanding the epidemiology and progression of systemic lupus erythematosus,” Seminars in Arthritis and Rheumatism, vol. 39, no. 4, pp. 257–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Dall'Era and E. F. Chakravarty, “Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies,” Current Rheumatology Reports, vol. 13, no. 4, pp. 308–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Namjou, J. Kilpatrick, and J. B. Harley, “Genetics of clinical expression in SLE,” Autoimmunity, vol. 40, no. 8, pp. 602–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Rahman and D. A. Isenberg, “Systemic lupus erythematosus,” New England Journal of Medicine, vol. 358, no. 9, pp. 929–939, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. P. P. Smith and C. Gordon, “Systemic lupus erythematosus: clinical presentations,” Autoimmunity Reviews, vol. 10, no. 1, pp. 43–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Kang, T. Quan, H. Nolasco et al., “Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus,” Journal of Immunology, vol. 172, no. 2, pp. 1287–1294, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. U. Y. Moon, S. J. Park, S. T. Oh et al., “Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood,” Arthritis Research & Therapy, vol. 6, no. 4, pp. R295–R302, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S.-F. Yu, H.-C. Wu, W.-C. Tsai et al., “Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan,” Medical Microbiology and Immunology, vol. 194, no. 3, pp. 115–120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Berkun, G. Zandman-Goddard, O. Barzilai et al., “Infectious antibodies in systemic lupus erythematosus patients,” Lupus, vol. 18, no. 13, pp. 1129–1135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-J. Chen, K.-H. Lin, S.-C. Lin et al., “High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies,” Journal of Rheumatology, vol. 32, no. 1, pp. 44–47, 2005. View at Google Scholar · View at Scopus
  11. D.-Y. Chen, Y.-M. Chen, J.-L. Lan et al., “Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?” Journal of Clinical Virology, vol. 49, no. 4, pp. 290–295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. B. A. Esen, G. YIlmaz, S. Uzun et al., “Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study,” Rheumatology International, vol. 32, no. 1, pp. 79–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. L. Huggins, I. Todd, and R. J. Powell, “Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus,” Rheumatology International, vol. 25, no. 3, pp. 183–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. James, K. M. Kaufman, A. D. Farris, E. Taylor-Albert, T. J. A. Lehman, and J. B. Harley, “An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus,” The Journal of Clinical Investigation, vol. 100, no. 12, pp. 3019–3026, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. James, B. R. Neas, K. L. Moser et al., “Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure,” Arthritis and Rheumatism, vol. 44, no. 5, pp. 1122–1126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J.-Y. Lu, D.-Y. Chen, C.-W. Hsieh, J.-L. Lan, F.-J. Lin, and S.-H. Lin, “Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan,” Lupus, vol. 16, no. 3, pp. 168–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. T. McClain, B. D. Poole, B. F. Bruner, K. M. Kaufman, J. B. Harley, and J. A. James, “An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 360–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. G. Parks, G. S. Cooper, L. L. Hudson et al., “Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1148–1159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Stratta, C. Canavese, G. Ciccone et al., “Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis,” Nephron, vol. 82, no. 2, pp. 145–154, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Zandman-Goddard, Y. Berkun, O. Barzilai et al., “Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease,” Annals of the New York Academy of Sciences, vol. 1173, pp. 658–663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. H. Draborg, J. M. Jørgensen, H. Müller et al., “Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients,” Scandinavian Journal of Rheumatology, vol. 41, no. 4, pp. 280–289, 2012. View at Publisher · View at Google Scholar
  22. D. Csuka, D. Simon, R. Hóbor et al., “Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis,” Clinical and Experimental Immunology, vol. 171, no. 3, pp. 255–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. B. R. Berner, M. Tary-Lehmann, N. L. Yonkers, A. D. Askari, P. V. Lehmann, and D. D. Anthony, “Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE,” Cellular Immunology, vol. 235, no. 1, pp. 29–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. G. C. Tsokos, I. T. Magrath, and J. E. Balow, “Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus,” Journal of Immunology, vol. 131, no. 4, pp. 1797–1801, 1983. View at Google Scholar · View at Scopus
  25. A. H. Draborg, S. Jacobsen, M. Westergaard et al., “Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients,” Lupus Science & Medicine, vol. 1, no. 1, Article ID e000015, 2014. View at Publisher · View at Google Scholar
  26. P. G. Auwaerter, “Infectious mononucleosis in middle age,” The Journal of the American Medical Association, vol. 281, no. 5, pp. 454–459, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Tattevin, Y. Le Tulzo, S. Minjolle et al., “Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study,” Journal of Clinical Microbiology, vol. 44, no. 5, pp. 1873–1874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. G. J. Babcock, D. Hochberg, and D. A. Thorley-Lawson, “The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell,” Immunity, vol. 13, no. 4, pp. 497–506, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. A. M. Joseph, G. J. Babcock, and D. A. Thorley-Lawson, “Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils,” Journal of Virology, vol. 74, no. 21, pp. 9964–9971, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Thorley-Lawson, “Epstein-Barr virus: exploiting the immune system,” Nature Reviews Immunology, vol. 1, no. 1, pp. 75–82, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Schepers, D. Pich, and W. Hammerschmid, “Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1,” Virology, vol. 220, no. 2, pp. 367–376, 1996. View at Publisher · View at Google Scholar · View at Scopus
  32. H. H. Niller, H. Wolf, and J. Minarovits, “Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases,” Autoimmunity, vol. 41, no. 4, pp. 298–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. N. M. Steven, N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson, “Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response,” Journal of Experimental Medicine, vol. 185, no. 9, pp. 1605–1617, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Setsuda, J. Teruya-Feldstein, N. L. Harris et al., “Interleukin-18, interferon-γ, IP-10, and Mig expression in Epstein- Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease,” American Journal of Pathology, vol. 155, no. 1, pp. 257–265, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. P. C. Azevedo, G. Murphy, and D. A. Isenberg, “Pathology of systemic lupus erythematosus: the challenges ahead,” Methods in Molecular Biology, vol. 1134, pp. 1–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Olferiev, M. Lliguicota, K. A. Kirou, and M. K. Crow, “Measuring interferon alpha and other cytokines in SLE,” Methods in Molecular Biology, vol. 1134, pp. 131–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. Yang, Y. Liang, B. Qin, and R. Zhong, “A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk,” Rheumatology International, vol. 34, no. 2, pp. 199–205, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Tiffin, A. Adeyemo, and I. Okpechi, “A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus,” Orphanet Journal of Rare Diseases, vol. 8, article 2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Larsen, D. Sauce, C. Deback et al., “Exhausted cytotoxic control of Epstein-barr virus in human lupus,” PLoS Pathogens, vol. 7, no. 10, Article ID e1002328, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. C. Hochberg, “Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 40, no. 9, article 1725, 1997. View at Google Scholar · View at Scopus
  41. K. Skogstrand, P. Thorsen, B. Nørgaard-Pedersen, D. E. Schendel, L. C. Sørensen, and D. M. Hougaard, “Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology,” Clinical Chemistry, vol. 51, no. 10, pp. 1854–1866, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Liao, J.-X. Lin, and W. J. Leonard, “IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation,” Current Opinion in Immunology, vol. 23, no. 5, pp. 598–604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. L. Croxford, P. Kulig, and B. Becher, “IL-12-and IL-23 in health and disease,” Cytokine and Growth Factor Reviews, vol. 25, no. 4, pp. 415–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Gattoni, A. Parlato, B. Vangieri, M. Bresciani, and R. Derna, “Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts),” Clinical Therapeutics, vol. 157, no. 5, pp. 457–468, 2006. View at Google Scholar
  45. D. Novick, S. Kim, G. Kaplanski, and C. A. Dinarello, “Interleukin-18, more than a Th1 cytokine,” Seminars in Immunology, vol. 25, no. 6, pp. 439–448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Ranasinghe, S. Trivedi, D. K. Wijesundara, and R. J. Jackson, “IL-4 and IL-13 receptors: roles in immunity and powerful vaccine adjuvants,” Cytokine and Growth Factor Reviews, vol. 25, no. 4, pp. 437–442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Takatsu, “Interleukin 5 and B cell differentiation,” Cytokine and Growth Factor Reviews, vol. 9, no. 1, pp. 25–35, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. H. T. Idriss and J. H. Naismith, “TNFα and the TNF receptor superfamily: structure-function relationship(s),” Microscopy Research and Technique, vol. 50, no. 3, pp. 184–195, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Körner and J. D. Sedgwick, “Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity,” Immunology and Cell Biology, vol. 74, no. 5, pp. 465–472, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. M. A. Santana and Y. Rosenstein, “What it takes to become an effector T cell: the process, the cells involved, and the mechanisms,” Journal of Cellular Physiology, vol. 195, no. 3, pp. 392–401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Miossec, T. Korn, and V. K. Kuchroo, “Interleukin-17 and type 17 helper T cells,” The New England Journal of Medicine, vol. 361, no. 9, pp. 848–898, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. C. A. Dinarello, “Historical insights into cytokines,” European Journal of Immunology, vol. 37, supplement 1, pp. S34–S45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Francisco-Cruz, M. Aguilar-Santelises, O. Ramos-Espinosa et al., “Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor,” Medical Oncology, vol. 31, article 774, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. A. H. Draborg, J. M. Jørgensen, H. Müller et al., “Epstein-Barrvirusearlyantigendiffuse(EBV-EA/D)-directedimmunoglobulin A antibodies in systemic lupus erythematosus patients,” Scandinavian Journal of Rheumatology, vol. 41, no. 4, pp. 280–289, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Groux, F. Cottrez, C. Montpellier et al., “Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus,” Blood, vol. 89, no. 12, pp. 4521–4530, 1997. View at Google Scholar · View at Scopus
  56. Y. Kasahara, A. Yachie, K. Takei et al., “Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection,” Blood, vol. 98, no. 6, pp. 1882–1888, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Kimura, Y. Hoshino, H. Kanegane et al., “Clinical and virologic characteristics of chronic active Epstein-Barr virus infection,” Blood, vol. 98, no. 2, pp. 280–286, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Kanegane, H. Wakiguchi, C. Kanegane, T. Kurashige, and G. Tosato, “Viral interleukin-10 in chronic active Epstein-Barr virus infection,” Journal of Infectious Diseases, vol. 176, no. 1, pp. 254–257, 1997. View at Publisher · View at Google Scholar · View at Scopus